ECB-ART-50064
Mol Clin Oncol
2013 Jul 01;14:575-581. doi: 10.3892/mco.2013.100.
Show Gene links
Show Anatomy links
Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.
Ulivi P
,
Zoli W
,
Capelli L
,
Chiadini E
,
Calistri D
,
Amadori D
.
???displayArticle.abstract???
In recent years, a number of new agents that target specific molecular pathways in non-small cell lung cancer (NSCLC) have been investigated. Much effort has been focused on identifying specific markers that are predictive of treatment response, given that a tailored approach would maximise the therapeutic index and cost-effectiveness. Gefitinib and erlotinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) and have produced good results in selected cases in terms of objective response rate and overall survival. At present, EGFR gene mutations are considered the most important predictors of clinical response to TKI therapy and tumour characterisation for these alterations is mandatory prior to any decision making. Echinoderm microtubule-like protein 4-anaplastic lymphoma kinase (EML4-ALK) translocation is another alteration capable of predicting the efficacy of anti-ALK agents, such as crizotinib. Moreover, emerging target agents, such as MET inhibitors, are likely to increase the amount of molecular characterisation required before a decision is made on treatment. The main limiting factor for adequate characterisation of metastatic NSCLC patients is the small quantity of tumour cells available for molecular analysis. In this study, we provided an overview of the most important and clinically relevant target agents in NSCLC patients as well as the most important mechanisms of resistance. The issue of the scant amount of biological samples available for analysis as well as alternative sampling approaches such as plasma- or serum-derived DNA were also examined.
???displayArticle.pubmedLink??? 24649213
???displayArticle.pmcLink??? PMC3915676
???displayArticle.link??? Mol Clin Oncol
References [+] :
Ahn,
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
2008, Pubmed
Ahn, Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? 2008, Pubmed
Alunni-Fabbroni, Circulating tumour cells in clinical practice: Methods of detection and possible characterization. 2010, Pubmed
Annema, Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer. 2005, Pubmed
Arcila, Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. 2011, Pubmed
Bai, Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. 2009, Pubmed
Balak, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. 2006, Pubmed
Bell, Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. 2005, Pubmed
Bergethon, ROS1 rearrangements define a unique molecular class of lung cancers. 2012, Pubmed
Birchmeier, Met, metastasis, motility and more. 2003, Pubmed
Brevet, Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. 2011, Pubmed
Cappuzzo, MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. 2009, Pubmed
Cappuzzo, Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. 2007, Pubmed
Chen, Inhibitors of the polymerase chain reaction in Papanicolaou stain. Removal with a simple destaining procedure. 1996, Pubmed
Chen, Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. 2012, Pubmed
Chen, EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. 2012, Pubmed
Choi, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. 2010, Pubmed , Echinobase
Chung, Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. 2010, Pubmed
Dahabreh, Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. 2010, Pubmed
Dongiovanni, Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? 2008, Pubmed
Engelman, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 2007, Pubmed
Gettinger, Targeted therapy in advanced non-small-cell lung cancer. 2008, Pubmed
Goto, Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. 2012, Pubmed
Greulich, Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. 2005, Pubmed
Gu, Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. 2009, Pubmed
Gupta, The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. 2009, Pubmed
He, Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. 2009, Pubmed
Hirsch, Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. 2007, Pubmed
Jiang, Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. 2005, Pubmed
Jiang, Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. 2011, Pubmed
Kimura, Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. 2006, Pubmed
Kimura, Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). 2007, Pubmed
Kobayashi, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. 2005, Pubmed
Koivunen, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. 2008, Pubmed
Kosaka, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. 2006, Pubmed
Kuang, Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. 2009, Pubmed
Kwak, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010, Pubmed
Lynch, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 2004, Pubmed
Mack, EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. 2009, Pubmed
Maheswaran, Detection of mutations in EGFR in circulating lung-cancer cells. 2008, Pubmed
Marchetti, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 2005, Pubmed
McDermott, Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. 2008, Pubmed
Mok, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. 2009, Pubmed
Mulloy, Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. 2007, Pubmed
Nakamura, Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. 2012, Pubmed
O'Flaherty, Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. 2012, Pubmed
Ou, Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. 2011, Pubmed
Oxnard, New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. 2011, Pubmed
Oxnard, Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. 2011, Pubmed
Paez, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004, Pubmed
Pantel, Circulating tumour cells in cancer patients: challenges and perspectives. 2010, Pubmed
Pao, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005, Pubmed
Pao, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 2004, Pubmed
Pao, Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. 2005, Pubmed
Punnoose, Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. 2012, Pubmed
Riely, Update on epidermal growth factor receptor mutations in non-small cell lung cancer. 2006, Pubmed
Rikova, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. 2007, Pubmed
Rosell, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. 2012, Pubmed
Rosell, Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. 2010, Pubmed
Rosell, Screening for epidermal growth factor receptor mutations in lung cancer. 2009, Pubmed
Sasaki, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. 2010, Pubmed
Sasaki, EGFR exon 20 insertion mutation in Japanese lung cancer. 2007, Pubmed
Savic, Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. 2008, Pubmed
Scagliotti, Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. 2007, Pubmed
Schneider, Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. 2008, Pubmed
Sequist, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. 2011, Pubmed
Sequist, Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. 2011, Pubmed
Sequist, Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. 2007, Pubmed
Sharma, Epidermal growth factor receptor mutations in lung cancer. 2007, Pubmed
Shaw, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009, Pubmed
Shigematsu, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. 2005, Pubmed
Smith, Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. 2008, Pubmed
Smouse, EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. 2009, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Sone, Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. 2007, Pubmed
Sordella, Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. 2004, Pubmed
Sozzi, Quantification of free circulating DNA as a diagnostic marker in lung cancer. 2003, Pubmed
Surati, Role of MetMAb (OA-5D5) in c-MET active lung malignancies. 2011, Pubmed
Takano, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. 2005, Pubmed
Takeuchi, Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. 2008, Pubmed
Taniguchi, Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. 2011, Pubmed
Tanizaki, Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. 2012, Pubmed
Taron, Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. 2005, Pubmed
Tournoy, EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. 2009, Pubmed
Tracy, Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. 2004, Pubmed
Ulivi, Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. 2012, Pubmed
Ulivi, EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients. 2012, Pubmed
Ulivi, Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue. 2013, Pubmed
Ulivi, Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. 2008, Pubmed
Yang, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. 2012, Pubmed
Yasuda, Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. 2012, Pubmed
Yung, Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. 2009, Pubmed